Normal view MARC view ISBD view

273P Long term outcomes of locally advanced & borderline resectable esthesioneuroblastoma and sinonasal tumour with neuroendocrine differentiation treated with neoadjuvant chemotherapy

In Annals of Oncology
By: Talreja V.
Material type: materialTypeLabelArticlePublisher: 2020Description: .Subject(s): Progression-free survival (PFS) | Overall survival (OS) | Neoadjuvant chemotherapy In: Annals of OncologySummary: Background The present analysis was done to estimate the 5-year outcomes and late adverse events of locally advanced sinonasal tumours treated with induction chemotherapy followed by local therapy. Methods Twenty-five patients with locally advanced esthesioneuroblastoma or sinonasal neuroendocrine tumours treated between August 2010 to August 2014 with induction chemotherapy followed by local therapy were selected. The 5-year outcome and late adverse events (CTCAE version 4.02) were noted. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan Meier method. COX regression analysis was used to identify factors impacting PFS and OS. Results The median follow-up was 5.15 years. The 5 year PFS in esthesioneuroblastoma cohort and in SNEC cohort was 63.5 %( 95%CI 28.9-84.7) and 34.6 % (95%CI 10.1-61.1) respectively (P=0.1). The only factor impacting PFS on multivariate analysis was a response to neoadjuvant chemotherapy (p=0.033). The 5 year OS in esthesioneuroblastoma cohort and in SNEC cohort were 91.7% (95%CI 53.9-98.9) and 46.2% (95%CI 19.2-69.6) respectively (p=0.024). Any grade late adverse event was seen in 20 patients (80%). Metabolic late adverse events were seen in 19 patients (76%). Conclusions Neoadjuvant chemotherapy in advanced sinonasal cancers is associated with improvement in 5-year outcomes. However, late side effects especially metabolic are seen in these patients and should be evaluated during follow up.
TMC TMH
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
Available AR20513

Abstract Book of the ESMO Asia Virtual Congress 2020 20-22 November 2020

Background
The present analysis was done to estimate the 5-year outcomes and late adverse events of locally advanced sinonasal tumours treated with induction chemotherapy followed by local therapy.
Methods
Twenty-five patients with locally advanced esthesioneuroblastoma or sinonasal neuroendocrine tumours treated between August 2010 to August 2014 with induction chemotherapy followed by local therapy were selected. The 5-year outcome and late adverse events (CTCAE version 4.02) were noted. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan Meier method. COX regression analysis was used to identify factors impacting PFS and OS.
Results
The median follow-up was 5.15 years. The 5 year PFS in esthesioneuroblastoma cohort and in SNEC cohort was 63.5 %( 95%CI 28.9-84.7) and 34.6 % (95%CI 10.1-61.1) respectively (P=0.1). The only factor impacting PFS on multivariate analysis was a response to neoadjuvant chemotherapy (p=0.033). The 5 year OS in esthesioneuroblastoma cohort and in SNEC cohort were 91.7% (95%CI 53.9-98.9) and 46.2% (95%CI 19.2-69.6) respectively (p=0.024). Any grade late adverse event was seen in 20 patients (80%). Metabolic late adverse events were seen in 19 patients (76%).
Conclusions
Neoadjuvant chemotherapy in advanced sinonasal cancers is associated with improvement in 5-year outcomes. However, late side effects especially metabolic are seen in these patients and should be evaluated during follow up.

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha